The hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections of the liver and, if left untreated, can result in fibrosis, permanent liver damage (cirrhosis), HCC, and eventually death. A member of the Flaviviridae viral family and hepacivirus genus, HCV can be classified into six major genotypes, with many additional subtypes within each genotype. While genotype 1 (GT1) causes almost half of HCV infections, all six major genotypes (GT1-6) are prevalent worldwide. The genetic diversity of HCV strains, even within the same host, originates from the low fidelity of the ribonucleic acid (RNA) polymerase, and is thought to account for viral resistance when HCV is treated with a single drug.
During the last few years, the hepatitis C treatment landscape has experienced successive waves of revolutionary change, and is now dominated by high-performance regimens comprising a new generation direct acting antivirals (DAAs). The treatment arsenal has rapidly expanded from only one unsatisfactory option-peginterferon plus ribavirin-to a collection of combination and fixed-dose combination regimens that can cure most patients in as little as 8?12 weeks, many without the use of interferon and/or ribavirin. Currently, these interferon-free and interferon-sparing DAA regimens dominate the treatment landscape as they combine a very high cure rate with improved tolerability and simplified dosing.
Global Data estimates that drug sales for hepatitis C in 2015 were approximately $21.7 billion across the 9MM. The global hepatitis C market is expected to experience a steady decline during the forecast period resulting in total sales of $17.5 billion by 2025, translating into a negative Compound Annual Growth Rate (CAGR) of 2.1%. The decline in sales will be most prominent in the US and in France, Germany, and the UK, while the southern European countries, Spain and Italy, as well as China, will see constant or even increasing market sizes during the forecast period.
The launch of multiple pan-genotypic DAA regimens will provide improved efficacy profiles for difficult-to-treat patients, including patients infected with genotype 3 (GT3), individuals with renal failure, and patients with decompensated liver cirrhosis.
The main barrier of future growth of the global HCV market will originate from the declining prevalence rates in most countries. Driven by modest treatment rates and excellent cure rates, the patient pools in most countries will steadily decline throughout the forecast; several markets will see significantly reduced total patient pools by 2025.
Key topics covered in report
HCV Genotypes Prevalent
Modes of HCV Transmission
Hepatitis C Virus Genotype Description
Hepatitis C Virus Therapeutics Drug Forecast
Symptoms of Acute and Chronic HCV Infection
Hepatitis C Virus Therapeutics Market Research
Global Hepatitis C Virus Therapeutics Market Analysis
Risk Factors and Comorbidities Associated with HCV Infection
For more coverage click on the link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
